DSB2455
Advanced Malignancies (with DDR deficiencies)
Phase 1a/1bActive
Key Facts
Indication
Advanced Malignancies (with DDR deficiencies)
Phase
Phase 1a/1b
Status
Active
Company
About Duke Street Bio
Duke Street Bio is a private, clinical-stage oncology biotech developing novel small molecules targeting DNA Damage Repair (DDR) pathways. Its core technology is centered on creating highly selective PARP1 inhibitors designed to overcome the hematological toxicity limitations of first-generation PARP inhibitors, thereby improving therapeutic index and enabling new combinations. The company's lead candidate, DSB2455, is a potent, CNS-penetrant PARP1 inhibitor in Phase 1a/1b trials, positioning it to potentially expand the treatable patient population in cancers with DDR defects.
View full company profile